Edwards Lifesciences Corp. (EW) has been embroiled in legal issues leading to major
stock depreciation. A class action lawsuit has been filed, accusing the firm of securities fraud. This is in response to a shocking 31% plummet in their stock value. All investors are encouraged to contact the filing law firm before the December 2024 deadline. The stock has also underperformed compared to its competitors, mainly due to failure to meet
earnings expectations and the release of a weak guidance report. This has led to major investors such as the New York State Common Retirement Fund offloading large quantities of their stock. However, the Q3 2024 earnings call highlighted a strong growth in TMTT sales, suggesting potential for turn around in the future.
Speculation about a potential takeover has surfaced as the company tries to overcome the TAVR headwinds. Despite the troubles, EW still retains a significant 85% institutional ownership and is seen as having solvable problems that offer excellent opportunities. This is enhanced by the fact that the company's
debt is manageable and their revenue growth is predicted to stay between 8%-10% for FY24.
Edwards Lifesciences Corp EW News Analytics from Thu, 25 Jul 2024 04:59:07 GMT to Sat, 02 Nov 2024 10:52:36 GMT -
Rating -7
- Innovation -5
- Information 2
- Rumor -6
